Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR125844 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| SAR125844 | EXPERIMENTAL | Given intravenously weekly at the dose of 570 mg/m\^2 for at least 18 weeks |
| Dose escalation | EXPERIMENTAL | SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m\^2), if the highest cleared dose in TED11449 is \>340 mg/m\^2. |
| Name | Type | Description |
|---|---|---|
| SAR125844 | DRUG | Pharmaceutical form:Concentrate for solution Route of administration: intravenous |
Inclusion criteria: Metastatic non-small-cell lung cancer patients with progressive disease during or after first or second line therapy harboring MET gene amplification and with measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Exclusion criteria: Patient less than...
SAR125844 is an investigational small molecule developed by Sanofi for the treatment of malignant solid tumors and neoplasm malignant. It has been studied in adult patients with advanced solid tumors and in non-small cell lung cancer (NSCLC) with MET amplification. It is not approved for any indication.
SAR125844 targets MET, a receptor tyrosine kinase. It acts as an inhibitor of MET. This targeted approach is designed to interfere with MET signaling, which can drive tumor growth and survival in cancers with MET alterations.
SAR125844 is being developed by Sanofi, a global pharmaceutical company. Sanofi's ticker symbol is SNY. The drug is part of Sanofi's oncology pipeline.
SAR125844 has been studied in Phase 1 and Phase 2 clinical trials. The Phase 1 trials are completed, and a Phase 2 trial in NSCLC with MET amplification is also completed. The drug remains investigational and has not been approved by the FDA.
SAR125844 has been evaluated in three completed clinical trials: NCT01391533, a Phase 1 trial in advanced solid tumors; NCT01657214, a Phase 1 dose escalation trial in Asian patients with solid tumors; and NCT02435121, a Phase 2 trial in NSCLC patients with MET amplification.